{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:54:44Z","timestamp":1791233684083,"version":"4.1.0"},"reference-count":116,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>The cardiovascular-kidney-metabolic (CKM) syndrome framework has important implications in the care of people with kidney diseases.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Cardiovascular screening is important in people with kidney diseases, but the approach may differ in this high-risk population.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Multiple pharmacotherapies for CKM syndrome offer significant cardiovascular and kidney benefits.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Cardiovascular-kidney-metabolic (CKM) syndrome highlights the interconnected nature of cardiovascular disease, CKD, and metabolic dysfunction and underscores the need for integrated approaches to prevention and treatment. Patients with kidney diseases are at markedly elevated risk for atherosclerotic cardiovascular events, heart failure, kidney failure, and premature mortality across the spectrum of kidney disease severity. Recent advances in therapeutics, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1)\u2013based therapies, and nonsteroidal mineralocorticoid receptor antagonists, alongside established renin-angiotensin system inhibitors and lipid-lowering therapies, have transformed the management of CKM by demonstrating both cardiovascular and kidney benefits. However, important gaps remain in applying the CKM framework to patients with kidney diseases, particularly among individuals with advanced CKD, kidney failure treated with dialysis, kidney transplant recipients, younger and older individuals, and those with nonmetabolic kidney diseases including glomerular disorders. This American Society of Nephrology Kidney Health Guidance provides practical guidance for nephrology clinicians on screening, risk stratification, and pharmacologic management across the CKM spectrum. The guidance emphasizes the importance of longitudinal assessment of estimated glomerular filtration rate and albuminuria as foundational markers of cardiovascular and kidney risk, including the role of cardiac biomarkers and imaging. Integration of cardiovascular and kidney risk prediction models, including the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations and the Kidney Failure Risk Equation (KFRE), may support early identification of high-risk patients and guide treatment intensification. The guidance also reviews evidence supporting sequential and combination approaches to CKM therapies, strategies for managing adverse effects, and special considerations for CKD subpopulations where data are more limited. Adoption of a CKM framework in nephrology practice promotes coordinated, multidisciplinary care and provides an opportunity to shift from organ-specific management toward a more holistic approach aimed at reducing cardiovascular events, slowing kidney disease progression, and improving patient-centered outcomes across the continuum of kidney disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Podcast<\/jats:title>\n                    <jats:p>This article contains a podcast at https:\/\/dts.podtrac.com\/redirect.mp3\/\/www.asn-online.org\/media\/podcast\/JASN\/2026_09_02_KTS_September2026.mp3<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.0000001231","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:00:31Z","timestamp":1788361231000},"page":"2282-2305","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic Syndrome"],"prefix":"10.1681","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9583-8628","authenticated-orcid":false,"given":"Nisha","family":"Bansal","sequence":"first","affiliation":[{"name":"Division of Nephrology, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5160-2947","authenticated-orcid":false,"given":"Petter","family":"Bjornstad","sequence":"additional","affiliation":[{"name":"Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Bress","sequence":"additional","affiliation":[{"name":"Population Health Sciences, University of Utah, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-1681","authenticated-orcid":false,"given":"Tara I.","family":"Chang","sequence":"additional","affiliation":[{"name":"Stanford Division of Nephrology, Department of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0542-8749","authenticated-orcid":false,"given":"Xingxing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Stanford Division of Nephrology, Department of Medicine, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8902-9576","authenticated-orcid":false,"given":"Michelle M.","family":"Estrella","sequence":"additional","affiliation":[{"name":"Renal Section, San Francisco VA Health Care System, Kidney Health Research Collaborative, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9109-0811","authenticated-orcid":false,"given":"Alan S.","family":"Go","sequence":"additional","affiliation":[{"name":"Division of Research (Cardiovascular, Kidney and Metabolic Health), Solutions Through Technology and Advanced Analytics Research (STAR) Group, Kaiser Permanente Northern California, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4258-1726","authenticated-orcid":false,"given":"Amy K.","family":"Mottl","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, University of North Carolina, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4953-7795","authenticated-orcid":false,"given":"Sankar D.","family":"Navaneethan","sequence":"additional","affiliation":[{"name":"Section of Nephrology and Institute of Clinical and Translational Research, Baylor College of Medicine and Renal Section, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, Royal North Shore Hospital, University of Sydney, UNSW Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-3744","authenticated-orcid":false,"given":"Brian S.","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Hattiesburg Clinic, Hattiesburg, Mississippi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Zuber","sequence":"additional","affiliation":[{"name":"American Academy of Nephrology Physician Assistants, Melbourne, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-7447","authenticated-orcid":false,"given":"Alexander R.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Geisinger, Danville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ASN Kidney Health Guidance Workgroup on the Cardiovascular-Kidney-Metabolic Syndrome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"20","key":"B1-20261005","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"B2-20261005","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1161\/CIR.0000000000001453","article-title":"2026 AHA\/ACC\/ADA\/ASN Guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome","volume":"154","author":"Ndumele","year":"2026","journal-title":"Circulation"},{"issue":"7-8","key":"B3-20261005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/0898264321991658","article-title":"Evidence for the 4Ms: interactions and outcomes across the care continuum","volume":"33","author":"Mate","year":"2021","journal-title":"J Aging Health."},{"issue":"4S","key":"B4-20261005","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"1","key":"B5-20261005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.7326\/ANNALS-25-02117","article-title":"Proteinuria or albuminuria as markers of kidney and cardiovascular disease risk: an individual patient-level meta-analysis","volume":"179","author":"Heerspink","year":"2026","journal-title":"Ann Intern Med."},{"issue":"5S","key":"B6-20261005","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"17","key":"B7-20261005","first-page":"e1154","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Blumenthal","year":"2026","journal-title":"Circulation."},{"issue":"18","key":"B8-20261005","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"B9-20261005","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"B10-20261005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jama.2015.18202","article-title":"Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis","volume":"315","author":"Tangri","year":"2016","journal-title":"JAMA."},{"key":"B11-20261005","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.0000001158","article-title":"A framework for risk-based implementation of combination therapy in CKD: who, why, when, and how?","author":"Yeung","year":"2026","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B12-20261005","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCULATIONAHA.123.067626","article-title":"Development and validation of the American Heart Association's PREVENT equations","volume":"149","author":"Khan","year":"2024","journal-title":"Circulation."},{"issue":"7","key":"B13-20261005","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1038\/s41591-026-04437-z","article-title":"Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals","volume":"32","author":"Neuen","year":"2026","journal-title":"Nat Med."},{"issue":"11","key":"B14-20261005","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1681\/ASN.0000000512","article-title":"ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases","volume":"35","author":"Ikizler","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"B15-20261005","doi-asserted-by":"crossref","first-page":"e140065","DOI":"10.1172\/JCI140065","article-title":"Dietary interventions for obesity: clinical and mechanistic findings","volume":"131","author":"Chao","year":"2021","journal-title":"J Clin Invest."},{"issue":"12","key":"B16-20261005","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med."},{"issue":"12","key":"B17-20261005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med."},{"issue":"8","key":"B18-20261005","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2409183","article-title":"Long-term effects of empagliflozin in patients with chronic kidney disease","volume":"392","author":"Herrington","year":"2025","journal-title":"N Engl J Med."},{"issue":"15","key":"B19-20261005","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med."},{"issue":"24","key":"B20-20261005","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"New England J Med"},{"issue":"2","key":"B21-20261005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"23","key":"B22-20261005","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med."},{"issue":"24","key":"B23-20261005","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med."},{"issue":"6","key":"B24-20261005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2604625","article-title":"Finerenone in persons with chronic kidney disease without diabetes","volume":"395","author":"Heerspink","year":"2026","journal-title":"N Engl J Med."},{"issue":"10","key":"B25-20261005","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa2512854","article-title":"Finerenone in type 1 diabetes and chronic kidney disease","volume":"394","author":"Heerspink","year":"2026","journal-title":"N Engl J Med."},{"issue":"10","key":"B26-20261005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med."},{"issue":"9","key":"B27-20261005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1161\/CIRCULATIONAHA.123.067620","article-title":"Mineralocorticoid receptor antagonism prevents aortic plaque progression and reduces left ventricular mass and fibrosis in patients with type 2 diabetes and chronic kidney disease: the MAGMA trial","volume":"150","author":"Rajagopalan","year":"2024","journal-title":"Circulation."},{"issue":"10504","key":"B28-20261005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(25)01194-8","article-title":"Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis","volume":"406","author":"Rossignol","year":"2025","journal-title":"Lancet."},{"issue":"1","key":"B29-20261005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med."},{"issue":"5","key":"B30-20261005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/PYFT6977","article-title":"Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT","volume":"29","author":"Hobbs","year":"2025","journal-title":"Health Technol Assess."},{"issue":"8","key":"B31-20261005","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2215\/CJN.09630818","article-title":"Clinical pharmacology in diuretic use","volume":"14","author":"Ellison","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6","key":"B32-20261005","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive medications and the prevalence of hyperkalemia in a large health system","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension."},{"issue":"19","key":"B33-20261005","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation."},{"issue":"7","key":"B34-20261005","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2025.10.049","article-title":"Risk of hyperkalemia with empagliflozin, finerenone, or both: secondary analysis of the CONFIDENCE randomized trial","volume":"87","author":"Agarwal","year":"2026","journal-title":"J Am Coll Cardiol."},{"issue":"48","key":"B35-20261005","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J."},{"issue":"10","key":"B36-20261005","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1002\/ejhf.300","article-title":"Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial","volume":"17","author":"Anker","year":"2015","journal-title":"Eur J Heart Fail."},{"issue":"14","key":"B37-20261005","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.05.079","article-title":"Patiromer facilitates angiotensin inhibitor and mineralocorticoid antagonist therapies in patients with heart failure and hyperkalemia","volume":"84","author":"Pitt","year":"2024","journal-title":"J Am Coll Cardiol."},{"issue":"6 Pt 2","key":"B38-20261005","doi-asserted-by":"crossref","first-page":"101823","DOI":"10.1016\/j.jacadv.2025.101823","article-title":"A critical appraisal of lipid management in the Post-statin era: comparison on guidelines, therapeutic targets, and screening in a case-based framework of lipid management","volume":"4","author":"Spitz","year":"2025","journal-title":"JACC Adv."},{"issue":"7","key":"B39-20261005","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1007\/s12325-025-03228-1","article-title":"Guideline-recommended disease-modifying therapies for patients with cardiorenal disease: a call-to-action narrative review","volume":"42","author":"Wanner","year":"2025","journal-title":"Adv Ther."},{"issue":"7","key":"B40-20261005","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin ii receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B41-20261005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jama.2025.20835","article-title":"Effects of sodium glucose cotransporter 2 inhibitors by diabetes status and level of albuminuria: a meta-analysis","volume":"335","author":"Staplin","year":"2026","journal-title":"JAMA."},{"issue":"5","key":"B42-20261005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/ANNALS-24-01926","article-title":"Evaluation and management of chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2024 clinical practice guideline","volume":"178","author":"Madero","year":"2025","journal-title":"Ann Intern Med."},{"issue":"2","key":"B43-20261005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/ndt\/gfaf132","article-title":"SGLT2 inhibitors and acute kidney injury","volume":"41","author":"Nakao","year":"2026","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"B44-20261005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2024.11.013","article-title":"Kidney and cardiovascular outcomes among patients with CKD receiving GLP-1 receptor agonists: a systematic review and meta-analysis of randomized trials","volume":"85","author":"Chen","year":"2025","journal-title":"Am J Kidney Dis."},{"issue":"11","key":"B45-20261005","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"16","key":"B46-20261005","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med."},{"issue":"10","key":"B47-20261005","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"B48-20261005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the randomized aldactone evaluation study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med."},{"issue":"9784","key":"B49-20261005","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet."},{"issue":"14","key":"B50-20261005","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med."},{"issue":"6","key":"B51-20261005","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2215\/CJN.09121010","article-title":"Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis","volume":"6","author":"Marz","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"B52-20261005","first-page":"CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","volume":"11","author":"Tunnicliffe","year":"2023","journal-title":"Cochrane Database Syst Rev."},{"issue":"42","key":"B53-20261005","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tunon","year":"2020","journal-title":"Eur Heart J."},{"issue":"23","key":"B54-20261005","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol."},{"issue":"1","key":"B55-20261005","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc."},{"issue":"15","key":"B56-20261005","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med."},{"issue":"10","key":"B57-20261005","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2215\/CJN.00370119","article-title":"The association of fenofibrate with kidney tubular injury in a subgroup of participants in the ACCORD trial","volume":"14","author":"Chauhan","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B58-20261005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med."},{"issue":"22","key":"B59-20261005","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","article-title":"Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: reduce-it RENAL","volume":"144","author":"Majithia","year":"2021","journal-title":"Circulation."},{"issue":"2","key":"B60-20261005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1056\/NEJMoa2513032","article-title":"Fish-oil supplementation and cardiovascular events in patients receiving hemodialysis","volume":"394","author":"Lok","year":"2026","journal-title":"N Engl J Med."},{"issue":"8","key":"B61-20261005","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2215\/CJN.0000000750","article-title":"GLP-1 receptor agonist outcomes, safety, and body mass index change in a national cohort of patients on dialysis","volume":"20","author":"Orandi","year":"2025","journal-title":"Clin J Am Soc Nephrol."},{"issue":"1","key":"B62-20261005","doi-asserted-by":"crossref","first-page":"108925","DOI":"10.1016\/j.jdiacomp.2024.108925","article-title":"Glucagon-like peptide-1 receptor agonists versus dipeptidyl-peptidase 4 inhibitors in advanced chronic kidney disease and end stage kidney disease: real world effectiveness and persistence of therapy","volume":"39","author":"Sidra","year":"2025","journal-title":"J Diabetes Complications."},{"issue":"10504","key":"B63-20261005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(25)01198-5","article-title":"Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial","volume":"406","author":"Walsh","year":"2025","journal-title":"Lancet."},{"issue":"3","key":"B64-20261005","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med."},{"issue":"6","key":"B65-20261005","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes","volume":"393","author":"Agarwal","year":"2025","journal-title":"N Engl J Med."},{"issue":"22","key":"B66-20261005","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.124.071689","article-title":"Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis","volume":"150","author":"Neuen","year":"2024","journal-title":"Circulation."},{"key":"B67-20261005","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.0000000973","article-title":"Risk assessment in cardiovascular-kidney-metabolic syndrome: an opportunity to individualize evidence-based therapy in CKD","author":"Gregg","year":"2025","journal-title":"Clin J Am Soc Nephrol."},{"issue":"6 Pt 2","key":"B68-20261005","doi-asserted-by":"crossref","first-page":"101788","DOI":"10.1016\/j.jacadv.2025.101788","article-title":"Lifestyle interventions in cardiovascular-kidney-metabolic syndrome JACC: advances expert panel","volume":"4","author":"Shahid","year":"2025","journal-title":"JACC Adv."},{"issue":"suppl 1","key":"B69-20261005","first-page":"S277","article-title":"Older adults: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"21","key":"B70-20261005","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1161\/CIR.0000000000001104","article-title":"Emerging evidence on coronary heart disease screening in kidney and liver transplantation candidates: a scientific statement from the American Heart Association: endorsed by the American Society of Transplantation","volume":"146","author":"Cheng","year":"2022","journal-title":"Circulation."},{"key":"B71-20261005","doi-asserted-by":"crossref","first-page":"100199","DOI":"10.1016\/j.obpill.2025.100199","article-title":"Obesity treatment as a bridge to solid organ transplantation: a comparison of bariatric surgery to medical therapy","volume":"16","author":"Roddy","year":"2025","journal-title":"Obes Pillars."},{"issue":"3","key":"B72-20261005","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int."},{"issue":"3","key":"B73-20261005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ndt\/gfad258","article-title":"International consensus on post-transplantation diabetes mellitus","volume":"39","author":"Sharif","year":"2024","journal-title":"Nephrol Dial Transplant."},{"issue":"6","key":"B74-20261005","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1053\/j.ajkd.2015.11.026","article-title":"Effects of dietary sodium restriction in kidney transplant recipients treated with renin-angiotensin-aldosterone system blockade: a randomized clinical trial","volume":"67","author":"de Vries","year":"2016","journal-title":"Am J Kidney Dis."},{"issue":"8","key":"B75-20261005","doi-asserted-by":"crossref","first-page":"e13302","DOI":"10.1111\/ctr.13302","article-title":"Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: a retrospective analysis of integrated registry and pharmacy claims data","volume":"32","author":"Vest","year":"2018","journal-title":"Clin Transplant."},{"issue":"3","key":"B76-20261005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/j.ajkd.2023.01.446","article-title":"Metformin use and long-term clinical outcomes in kidney transplant recipients","volume":"82","author":"Kwon","year":"2023","journal-title":"Am J Kidney Dis."},{"key":"B77-20261005","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.0000001195","article-title":"Evidence-based cardiovascular\u2013kidney\u2013metabolic therapies in kidney transplant recipients","author":"Shroff","year":"2026","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"B78-20261005","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.ajkd.2011.07.019","article-title":"Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients","volume":"59","author":"Marechal","year":"2012","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B79-20261005","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.ajkd.2016.08.018","article-title":"Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials","volume":"69","author":"Hiremath","year":"2017","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"B80-20261005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S2352-4642(25)00302-5","article-title":"Under pressure: the lifelong cardiovascular health of children and youth with primary hypertension","volume":"10","author":"Chanchlani","year":"2026","journal-title":"Lancet Child Adolesc Health."},{"issue":"8","key":"B81-20261005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S2352-4642(25)00127-0","article-title":"Long-term kidney outcomes in children and adolescents with hypertension: a propensity-matched cohort study","volume":"9","author":"Hussain","year":"2025","journal-title":"Lancet Child Adolesc Health."},{"issue":"2","key":"B82-20261005","doi-asserted-by":"crossref","first-page":"e1921213","DOI":"10.1001\/jamanetworkopen.2019.21213","article-title":"Association of time-varying blood pressure with chronic kidney disease progression in children","volume":"3","author":"Reynolds","year":"2020","journal-title":"JAMA Netw Open."},{"issue":"5","key":"B83-20261005","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41366-024-01710-4","article-title":"Association between early age body mass index and the risk of adulthood cardiovascular diseases: a systematic review and meta-analysis","volume":"49","author":"Qiu","year":"2025","journal-title":"Int J Obes (Lond)."},{"issue":"25","key":"B84-20261005","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1056\/NEJMoa1503840","article-title":"Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood","volume":"374","author":"Twig","year":"2016","journal-title":"N Engl J Med."},{"key":"B85-20261005","doi-asserted-by":"crossref","DOI":"10.1038\/s41366-026-02091-6","article-title":"Association of childhood-to-adulthood body size trajectories with cardiovascular risk and all cause mortality","author":"Tang","year":"2026","journal-title":"Int J Obes (Lond)."},{"issue":"2","key":"B86-20261005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jamapediatrics.2023.5420","article-title":"Adolescent body mass index and early chronic kidney disease in young adulthood","volume":"178","author":"Tsur","year":"2024","journal-title":"JAMA Pediatr."},{"issue":"10","key":"B87-20261005","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/archdischild-2011-300685","article-title":"Puberty is associated with increased deterioration of renal function in patients with CKD: data from the ItalKid Project","volume":"97","author":"Ardissino","year":"2012","journal-title":"Arch Dis Child."},{"issue":"2","key":"B88-20261005","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.ackd.2005.01.005","article-title":"Pediatric aspects of diabetic kidney disease","volume":"12","author":"Lane","year":"2005","journal-title":"Adv Chronic Kidney Dis."},{"issue":"4","key":"B89-20261005","doi-asserted-by":"crossref","first-page":"e1004553","DOI":"10.1371\/journal.pmed.1004553","article-title":"Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: an individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events","volume":"22","author":"Wightman","year":"2025","journal-title":"PLoS Med."},{"issue":"3","key":"B90-20261005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40266-025-01183-8","article-title":"Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in older adults with variable disease states: a meta-analysis of large placebo-controlled trials","volume":"42","author":"Shah","year":"2025","journal-title":"Drugs Aging."},{"key":"B91-20261005","doi-asserted-by":"crossref","first-page":"105981","DOI":"10.1016\/j.archger.2025.105981","article-title":"Efficacy of GLP-1 receptor agonists among older adults: a meta-analysis of cardio-kidney outcome trials","volume":"138","author":"Waqas","year":"2025","journal-title":"Arch Gerontol Geriatr."},{"key":"B92-20261005","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.2147\/DDDT.S531778","article-title":"Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: a 24-month retrospective cohort study","volume":"19","author":"Ren","year":"2025","journal-title":"Drug Des Devel Ther."},{"issue":"1","key":"B93-20261005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/bcp.70253","article-title":"Semaglutide use is associated with neuromuscular junction degradation in older adults with type II diabetes mellitus","volume":"92","author":"Qaisar","year":"2026","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"B94-20261005","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000513869","article-title":"Association of obesity with cardiovascular risk factors and kidney disease outcomes in primary proteinuric glomerulopathies","volume":"145","author":"Shah","year":"2021","journal-title":"Nephron."},{"issue":"3","key":"B95-20261005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1053\/j.ajkd.2024.03.020","article-title":"Association of obesity with kidney and cardiac outcomes among patients with glomerular disease: findings from the cure glomerulonephropathy network","volume":"84","author":"Zeitler","year":"2024","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B96-20261005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.ajkd.2022.04.005","article-title":"The risk of cardiovascular events in individuals with primary glomerular diseases","volume":"80","author":"Canney","year":"2022","journal-title":"Am J Kidney Dis."},{"issue":"6","key":"B97-20261005","doi-asserted-by":"crossref","first-page":"100877","DOI":"10.1016\/j.xkme.2024.100877","article-title":"Cardiovascular and thromboembolic events in children and adults with glomerular disease: findings from the cure glomerulonephropathy (CureGN) network","volume":"7","author":"Wadhwani","year":"2025","journal-title":"Kidney Med."},{"issue":"1","key":"B98-20261005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12882-018-0878-5","article-title":"Cardiovascular outcomes of nephrotic syndrome in childhood (CVONS) study: a protocol for prospective cohort study","volume":"19","author":"Patnaik","year":"2018","journal-title":"BMC Nephrol."},{"issue":"5","key":"B99-20261005","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00467-019-04434-0","article-title":"Augmentation index, a predictor of cardiovascular events, is increased in children and adolescents with primary nephrotic syndrome","volume":"35","author":"Alves","year":"2020","journal-title":"Pediatr Nephrol."},{"issue":"3","key":"B100-20261005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.semnephrol.2018.02.009","article-title":"Cardiovascular disease risk in children with kidney disease","volume":"38","author":"Sethna","year":"2018","journal-title":"Semin Nephrol."},{"issue":"9","key":"B101-20261005","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00467-019-04301-y","article-title":"Dyslipidemia and cardiovascular health in childhood nephrotic syndrome","volume":"35","author":"Hari","year":"2020","journal-title":"Pediatr Nephrol."},{"issue":"1","key":"B102-20261005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int."},{"issue":"1","key":"B103-20261005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"Group","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"B104-20261005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.kint.2025.04.003","article-title":"Executive summary of the KDIGO 2025 clinical practice guideline for the management of immunoglobulin a nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Floege","year":"2025","journal-title":"Kidney Int."},{"issue":"4","key":"B105-20261005","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1681\/ASN.0000000943","article-title":"Sodium-glucose cotransporter 2 inhibitors in autosomal dominant polycystic kidney disease: mechanistic insights and therapeutic promise","volume":"37","author":"Bou Antoun","year":"2026","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B106-20261005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jama.2026.9923","article-title":"Finerenone in patients with chronic kidney disease due to glomerular diseases: a randomized clinical trial","volume":"336","author":"Neuen","year":"2026","journal-title":"JAMA."},{"issue":"2","key":"B107-20261005","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1600-6143.2009.02949.x","article-title":"Predicting coronary heart disease after kidney transplantation: patient outcomes in renal transplantation (PORT) study","volume":"10","author":"Israni","year":"2010","journal-title":"Am J Transplant."},{"issue":"1","key":"B108-20261005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s12035-025-05549-2","article-title":"Calcineurin inhibitors: current role, toxicity management, and future frontiers in immunosuppression","volume":"63","author":"Mistry","year":"2025","journal-title":"Mol Neurobiol."},{"issue":"5","key":"B109-20261005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40620-014-0103-y","article-title":"mTOR inhibitors and renal allograft: Yin and Yang","volume":"27","author":"Zaza","year":"2014","journal-title":"J Nephrol."},{"issue":"4","key":"B110-20261005","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf."},{"issue":"20","key":"B111-20261005","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation."},{"issue":"2","key":"B112-20261005","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.ajkd.2020.01.007","article-title":"CKD awareness among US adults by future risk of kidney failure","volume":"76","author":"Chu","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B113-20261005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.akdh.2023.08.003","article-title":"Medication adherence among patients with kidney disease: an umbrella review","volume":"31","author":"Tesfaye","year":"2024","journal-title":"Adv Kidney Dis Health."},{"issue":"11","key":"B114-20261005","doi-asserted-by":"crossref","first-page":"100545","DOI":"10.1016\/j.xkme.2022.100545","article-title":"Treatment adherence in CKD and support from health care providers: a qualitative study","volume":"4","author":"Rivera","year":"2022","journal-title":"Kidney Med."},{"issue":"4","key":"B115-20261005","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2025.03.017","article-title":"The delivery of kidney care in rural or sparsely populated settings","volume":"86","author":"Koppula","year":"2025","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B117-20261005","doi-asserted-by":"crossref","first-page":"e2453684","DOI":"10.1001\/jamanetworkopen.2024.53684","article-title":"Academic detailing interventions and evidence-based prescribing: a systematic review","volume":"8","author":"Rome","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:00:44Z","timestamp":1791230444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":116,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.0000001231","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}